General Product Information


Aconitase Colorimetric Assay Kit


Oxis International, Inc.


request a price quotation on Aconitase Colorimetric Assay Kit from Oxis International Inc

Catalog Number



1 x 100

Assay Range

1-80 Units/ml of reaction mixture


Request Info




1.71 Units/ml of reaction mixture


Aconitase Assays

Detection Target


Request Information

request information about Aconitase Colorimetric Assay Kit Oxis International Inc

More Information

Company Product Page external link

Product Description

Aconitase belongs to the class of hydratase enzymes, catalyzing the isomerization of citrate to isocitrate via the intermediate, cis-aconitate. Citrate is isomerized by aconitase into isocitrate, enabling the six-carbon unit to undergo oxidative decarboxylation, catalyzed by isocitrate dehydrogenase, to form a-ketoglutarate. The BIOXYTECH Aconitase-340™ Assay is based on measurement of the concomitant formation of NADPH from NADP+. The formation of NADPH is monitored by the increase in absorbance at 340nm. Under appropriate conditions, the rate of NADPH production is proportional to aconitase activity. The concentration of aconitase is expressed in units of activity. One aconitase unit will convert 1.0 µmol of citrate to isocitrate per minute at 25°C and pH 7.4. is equal to the consumption of NADP+, measured as the increase in absorbance at 340 nm. Because the Aconitase-340™ assay is carried out at 37°C, OXIS has determined a temperature coefficient to correct for increased aconitase activity at 37°C. Please note that in the citric acid cycle, NAD+ is reduced to NADH. However, the use of NADP+ significantly improves assay performance.

  • Species:     Multiple
  • Detection Target name:     Catalase
  • Target Synonyms:     Catalase
  • Method:     Colorimetric
  • Regulatory status:     RUO
  • Sample type:     Tissue homogenate, cell lysate, whole blood, serum, or plasma
  • Assay time:     1 hour

The legacy of Marie Schlau: literature to help cure Friedreich's Ataxia

If you feel like reading an unputdownable novel while collaborating with a just and solidary cause, "The Legacy of Marie Schlau" is your book! 100% of all funds raised will be dedicated to medical research to find a cure for Friedreich's Ataxia, a neurodegenerative disease that affects mostly young people, shortening their life expectancy and confining them to a wheelchair.

The life of Marie Schlau, a German Jewish girl born in 1833 hides great unsolved mysteries: accidents, disappearances, enigmas, unknown diagnoses, disturbing murders, love, tenderness, greed, lies, death ... alternatively a different story unfolds every time and takes us closer to the present. Thus, there are two parallel stories unravelling, each in a different age and place, which surprisingly converge in a revelatory chapter.

Paperback and Kindle versions for "The legacy of Marie Schlau" available for sale at Amazon now!


Research projects currently being financed by BabelFAmily

Currently, BabelFAmily is financing two promising research projects aimed at finding a cure for Friedreich's Ataxia. Whenever you make a donation to us or purchase a copy of "The legacy of Marie Schlau", this is where all funds raised will be devoted to:

1) Gene Therapy for Friedreich's Ataxia research project:

The project is the result of an initiative of Spanish people affected by this rare disease who are grouped in GENEFA in collaboration with the Spanish Federation of Ataxias and the BabelFAmily. The Friedreich’s Ataxia Research Alliance (FARA), one of the main patients’ associations in the United States now joins the endeavour.

2) Frataxin delivery research project:
The associations of patients and families Babel Family and the Asociación Granadina de la Ataxia de Friedreich (ASOGAF) channel 80,000 euros of their donations (50% from each organisation) into a new 18-month project at the Institute for Research in Biomedicine (IRB Barcelona). The project specifically aims to complete a step necessary in order to move towards a future frataxin replacement therapy for the brain, where the reduction of this protein causes the most damage in patients with Friedreich’s Ataxia.

The study is headed by Ernest Giralt, head of the Peptides and Proteins Lab, who has many years of experience and is a recognised expert in peptide chemistry and new systems of through which to delivery drugs to the brain, such as peptide shuttles—molecules that have the capacity to carry the drug across the barrier that surrounds and protects the brain. Since the lab started its relation with these patients’ associations in 2013*, it has been developing another two projects into Friedrich’s Ataxia.



Go to top